| Aug 9 |
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 6 |
Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
|
| Jul 16 |
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
|
| Jun 11 |
Wolfe Research starts Akero at outperform, cites MASH drug prospects
|
| Jun 11 |
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
|
| Jun 8 |
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
|
| Jun 5 |
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
|
| May 29 |
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
|
